Why the study?
The study aimed to explore the correlation between Ang-1, Ang-2, and the Ang-2/Ang-1 ratio with clinical outcomes to potentially serve as disease severity and survival biomarkers in COVID-19.
Do Ang-1, Ang-2, and the Ang-2/Ang-1 ratio correlate with disease severity in COVID-19 patients?
Do Ang-1, Ang-2, and the Ang-2/Ang-1 ratio correlate with disease severity in COVID-19 patients?
The Ang-2/Ang-1 ratio serves as a potential biomarker for endothelial dysfunction and disease severity in COVID-19 patients, aiding in risk stratification.
May support Ang-2/Ang-1 ratio as COVID-19 severity biomarker; leaves open prospective validation before clinical use.
The study aimed to explore the correlation among angiopoietin-1, (Ang-1) and Angiopoietin-2, (Ang-2) concentrations and the Angiopoietin-2/Angiopoietin-1 ratio, (Ang-2/Ang-1) with clinical outcomes, potentially serving as disease severity and survival biomarkers. A study at AHEPA University Hospital involved 90 COVID-19 adult patients, with 30 hospitalized in intensive care and 30 in ward units and 30 asymptomatic non-hospitalized individuals as controls. Estimated endothelial dysfunction markers related to angiogenesis were measured, and statistical analysis was performed using IBM SPSS Statistics software, version 29. There was a statistically significant difference only between outpatient and hospitalized patients (non-ICU -ICU groups) for the Ang-1 and Ang-2 indexes. The Ang-2/Ang-1 ratio has differed significantly among all individual patient groups. A ROC analysis was conducted to find an optimal threshold for distinguishing (outpatients – non-ICU) and (non-ICU – ICU) groups. It was based on Youden's Index and was 0.1122 or 0.1271 and 0.3825 or 0.4510, respectively. The Ang-1, Ang-2 levels, and Ang-2 / Ang-1 ratio were analysed as indicators for severity in COVID-19 patients. The Ang-2 / Ang-1 ratio demonstrated more excellent prognostic and diagnostic utility than individual biomarker levels. Monitoring the Ang-2/Ang-1 ratio can identify COVID-19 patients at risk and assist clinicians in tailoring treatment strategies for improved outcomes.
No takes yet. Share an insight, caveat, or question.
Τσιάτσιου et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: